Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Master's Program Graduate Research Scholarship
EF 2023-24
Résumé
Ovarian cancer (OC) is the most lethal gynecological cancer. Immunotherapy, a treatment that helps the immune system fight cancer, has achieved remarkable responses in cancer types that were once fatal. Its successes have brought new hope to OC patients; however, the latest OC clinical trials have shown overall disappointing responses with immune checkpoint blockade (ICB), the most common type of immunotherapy. The interaction between OC and immune cells is influenced by various factors that alter the immune response and contribute to disease progression. Our research team is studying how to target these factors to improve the treatment of OC. One particular target is the SWI/SNF complex, made up of proteins involved in modifying the structure of DNA. In our recent study, we discovered that inhibiting the function of this complex increases the ability of OC cells to be recognized by the immune system. Another protein target, called HDAC6, that makes DNA less accessible has also been shown, when its function is inhibited, to increase the expression of immune-related genes. Based on these findings, targeting both factors is a logical therapeutic strategy to sensitize OC to immunotherapy for a more effective response. Therefore, we propose in our study to combine HDAC6 and SWI/SNF inhibitors with ICB. This novel study may be used to overcome barriers to immunotherapy and help us reach our goal to improve the outcomes for patients with OC.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506448
Name
Mckeeman Olivia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Master's Program Graduate Research Scholarship
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brg1; Chromatin Remodeling; Epigenetic Therapy; Immune Checkpoint Blockade; Immune Tumor Microenvironment; Ovarian Cancer
Abstract
Ovarian cancer (OC) is the most lethal gynecological cancer. Immunotherapy, a treatment that helps the immune system fight cancer, has achieved remarkable responses in cancer types that were once fatal. Its successes have brought new hope to OC patients; however, the latest OC clinical trials have shown overall disappointing responses with immune checkpoint blockade (ICB), the most common type of immunotherapy. The interaction between OC and immune cells is influenced by various factors that alter the immune response and contribute to disease progression. Our research team is studying how to target these factors to improve the treatment of OC. One particular target is the SWI/SNF complex, made up of proteins involved in modifying the structure of DNA. In our recent study, we discovered that inhibiting the function of this complex increases the ability of OC cells to be recognized by the immune system. Another protein target, called HDAC6, that makes DNA less accessible has also been shown, when its function is inhibited, to increase the expression of immune-related genes. Based on these findings, targeting both factors is a logical therapeutic strategy to sensitize OC to immunotherapy for a more effective response. Therefore, we propose in our study to combine HDAC6 and SWI/SNF inhibitors with ICB. This novel study may be used to overcome barriers to immunotherapy and help us reach our goal to improve the outcomes for patients with OC.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mckeeman, Olivia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~